Opinion|Videos|January 9, 2024

New Opportunities via Novel Formulation Technologies

Ascendia Pharmaceuticals CEO, Jim Huang, describes how new opportunities in formulation development complement the company’s previous work in developing novel nanotechnologies to support biopharmaceutical development.

Jim Huang, CEO of Ascendia Pharmaceuticals discusses:

  • Ascendia Pharmaceuticals growth and culture
  • Recent advances including the company's fourth nanotechnology – LipidSol

Related to this article

AAPS PharmSci 360 2026: Roller-Compacted Formulations
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.